|
A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen Clinical research trials and A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen. A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen clinical trial. Human subjects often receive the most effective healthcare possible for their A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen  A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen
A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen
For Condition: Chronic Hepatitis B
Status: No longer recruiting
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen negative.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: - Male and female subjects =/> 16 years of age (or minimum age required in a given country) with history of chronic hepatitis B infection; - HBeAg negative, anti-HBeAb positive; - Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV); - Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease; - Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine)
Total Enrollment:
Location and Contact Information:
Local Investigator
Worcester, Massachusetts,
United States
Local Investigator
Dundalk, Maryland,
United States
Local Investigator
Richmond, Virginia,
United States
Local Investigator
Providence, Rhode Island,
United States
Local Investigator
Orange, California,
United States
Local Investigator
Ann Arbor, Michigan,
United States
Local Investigator
Charlotte, North Carolina,
United States
Local Investigator
Rochester, New York,
United States
Local Investigator
Miami, Florida,
United States
Local Investigator
Seattle, Washington,
United States
Local Investigator
Los Angeles, California, 90048
United States
Local Investigator
Cleveland, Ohio,
United States
Local Investigator
Manhasset, New York,
United States
Local Investigator
Philadelphia, Pennsylvania,
United States
Local Investigator
La Jolla, California,
United States
Local Investigator
Dallas, Texas,
United States
Local Investigator
Atlanta, Georgia, 30322
United States
Local Investigator
Honolulu, Hawaii,
United States
Local Investigator
San Francisco, California,
United States
Local Investigator
New York City, New York,
United States
Local Investigator
Iowa City, Iowa,
United States
Local Investigator
Birmingham, Alabama,
United States
Local Investigator
Royal Oak, Michigan,
United States
Local Investigator
Nashville, Tennessee, 37211
United States
Local Investigator
New York City, New York,
United States
Local Investigator
Chicago, Illinois, 60622
United States
Local Investigator
Fairfax, Virginia,
United States
Local Investigator
Tucson, Arizona,
United States
Local Investigator
New York City, New York,
United States
Local Investigator
Pittsburgh, Pennsylvania,
United States
Local Investigator
Farmington, Connecticut,
United States
Local Investigator
St. Paul, Minnesota,
United States
Local Investigator
Kansas City, Kansas,
United States
Additional Information:
Study ID Numbers: AI463-027;
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035789
Other Chronic Hepatitis B Studies:
1. A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects with Incomplete Response to Lamivudine
2. Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients with Chronic Hepatitis B
3. Safety and antiviral study of ACH126, 433 (b-L-Fd4C) in adults with lamivudine-resistant chronic hepatitis B
4. Safety and antiviral study of ACH-126, 443 (beta-L-Fd4C) in the treatment of adults with chronic Hepatitis B infection.
5. Efficacy and safety study of Pegasys in the treatment of chronic hepatitis B
Related Studies:
Other Chronic Hepatitis B Clinical Trials
Other North Carolina Clinical Trials
Other Charlotte Clinical Trials
A Phase III Study of Entecavir vs Lamivudine in Adults with Chronic Hepatitis B Infection and negative for Hepatitis B e Antigen
|
|
|
|
|
|
|
|
